NCT05946798 Role of NADPH Oxidase in Microvascular Dysfunction Following GDM
| NCT ID | NCT05946798 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | Anna Stanhewicz, PhD |
| Condition | Gestational Diabetes |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2023-08-30 |
| Primary Completion | 2027-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 40 participants in total. It began in 2023-08-30 with a primary completion date of 2027-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this investigation is to examine NADPH oxidase as a source of reactive oxygen species contributing to aberrant microvascular function in otherwise healthy women with a history of GDM.
Eligibility Criteria
INCLUSION CRITERIA: * 18 years or older * pregnant within 5 years of the study visit * had gestational diabetes diagnosed by their obstetrician and confirmed according to the American College of Obstetricians and Gynecologists criteria for gestational diabetes. * or without a history of gestational diabetes EXCLUSION CRITERIA: * skin diseases * current tobacco or electronic cigarette/vape pen use, * diagnosed or suspected hepatic or metabolic disease including diabetes, * statin or other cholesterol-lowering medication, * current antihypertensive medication, * history of preeclampsia or gestational hypertension, * current pregnancy, * body mass index \<18.5 kg/m2, * allergy to materials used during the experiment.(e.g. latex), * known allergies to study drugs
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05946798 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 50 Years, studying Gestational Diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05946798 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT05946798 currently recruiting?
Yes, NCT05946798 is actively recruiting participants. Contact the research team at anna-stanhewicz@uiowa.edu for enrollment information.
Where is the NCT05946798 trial being conducted?
This trial is being conducted at Iowa City, United States.
Who is sponsoring the NCT05946798 clinical trial?
NCT05946798 is sponsored by Anna Stanhewicz, PhD. The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.